Literature DB >> 18391217

Cytidine deamination induced HIV-1 drug resistance.

Lubbertus C F Mulder1, Ariana Harari, Viviana Simon.   

Abstract

The HIV-1 Vif protein is essential for overcoming the antiviral activity of DNA-editing apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 (APOBEC3) cytidine deaminases. We show that naturally occurring HIV-1 Vif point mutants with suboptimal anti-APOBEC3G activity induce the appearance of proviruses with lamivudine (3TC) drug resistance-associated mutations before any drug exposure. These mutations, ensuing from cytidine deamination events, were detected in >40% of proviruses with partially defective Vif mutants. Transfer of drug resistance from hypermutated proviruses via recombination allowed for 3TC escape under culture conditions prohibitive for any WT viral growth. These results demonstrate that defective hypermutated genomes can shape the phenotype of the circulating viral population. Partially active Vif alleles resulting in incomplete neutralization of cytoplasmic APOBEC3 molecules are directly responsible for the generation of a highly diverse, yet G-to-A biased, proviral reservoir, which can be exploited by HIV-1 to generate viable and drug-resistant progenies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391217      PMCID: PMC2291111          DOI: 10.1073/pnas.0710190105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Intrinsic immunity: a front-line defense against viral attack.

Authors:  Paul D Bieniasz
Journal:  Nat Immunol       Date:  2004-11       Impact factor: 25.606

Review 3.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 4.  Update of the drug resistance mutations in HIV-1: 2007.

Authors:  Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2007 Aug-Sep

5.  APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.

Authors:  Mark T Liddament; William L Brown; April J Schumacher; Reuben S Harris
Journal:  Curr Biol       Date:  2004-08-10       Impact factor: 10.834

6.  Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.

Authors:  Yong-Hui Zheng; Dan Irwin; Takeshi Kurosu; Kenzo Tokunaga; Tetsutaro Sata; B Matija Peterlin
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Human immunodeficiency virus evolution towards reduced replicative fitness in vivo and the development of AIDS.

Authors:  Dominik Wodarz; David N Levy
Journal:  Proc Biol Sci       Date:  2007-10-07       Impact factor: 5.349

9.  Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.

Authors:  Rebecca A Russell; Vinay K Pathak
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

10.  Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Authors:  Kun Luo; Tao Wang; Bindong Liu; Chunjuan Tian; Zuoxiang Xiao; John Kappes; Xiao-Fang Yu
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

View more
  94 in total

1.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution.

Authors:  Shai Carmi; George M Church; Erez Y Levanon
Journal:  Nat Commun       Date:  2011-11-01       Impact factor: 14.919

5.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 6.  The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential.

Authors:  Christopher S Nabel; Sara A Manning; Rahul M Kohli
Journal:  ACS Chem Biol       Date:  2011-10-31       Impact factor: 5.100

7.  Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Authors:  Satish K Pillai; Mohamed Abdel-Mohsen; John Guatelli; Mark Skasko; Alexander Monto; Katsuya Fujimoto; Steven Yukl; Warner C Greene; Helen Kovari; Andri Rauch; Jacques Fellay; Manuel Battegay; Bernard Hirschel; Andrea Witteck; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard; Joseph K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

8.  Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels.

Authors:  Masako Nomaguchi; Naoya Doi; Yosuke Sakai; Hirotaka Ode; Yasumasa Iwatani; Takamasa Ueno; Yui Matsumoto; Yasuyuki Miyazaki; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

9.  APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element.

Authors:  Roni Nowarski; Ponnandy Prabhu; Edan Kenig; Yoav Smith; Elena Britan-Rosich; Moshe Kotler
Journal:  J Mol Biol       Date:  2014-05-21       Impact factor: 5.469

Review 10.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.